focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied Materials
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied MaterialsView Video
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to mining
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to miningView Video

Latest Share Chat

Pin to quick picksSyncona Share News (SYNC)

Share Price Information for Syncona (SYNC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 112.20
Bid: 112.00
Ask: 113.00
Change: 0.00 (0.00%)
Spread: 1.00 (0.893%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 112.20
SYNC Live PriceLast checked at -
Syncona is an Investment Trust

To deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Molten Ventures completes raise; Saietta proposes one

Mon, 27th Nov 2023 19:03

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

----------

Saietta Group PLC - Towcester, England-based designer, engineer and manufacturer of 'eDrive' solutions for electric vehicles - Proposes placing and subscription of new shares to raise a minimum GBP5.2 million, pricing each share at 17 pence each. This is alongside a broker option to Canaccord Genuity Ltd for an additional GBP1.0 million. The fundraising is being conducted in two tranches: around GBP1.7 million raised via the firm fundraising and a minimum of GBP4.7 million via a conditional fundraising. The fundraising is expected to satisfy the company's working capital requirements through to the end of March 2024, by which time the company is expecting to have announced a number of major commercial developments.

----------

Syncona Ltd - London-based investor in healthcare companies - Notes that its portfolio company Autolus Therapeutics PLC submits biologics licence application to US Food & Drug Administration for obecabtagene autoleucel for patients with relapsed/refractory adult B-Cell acute lymphoblastic leukaemia. Says submission is based on data from the Felix study. Says Autolus has also made "significant" progress in preparing its manufacturing footprint for the planned commercial launch of obe-cel, with its new 70,000 square foot commercial manufacturing facility, The Nucleus, which has an initial designed capacity of 2,000 batches per year. Pending approval from the Food & Drug Administration for the biologics licence application submission, the company expects to initiate its commercial launch of obe-cel in the US in 2024. It also expects to file a marketing authorisation application for obe-cel with the European Medicines Agency in the first half of 2024.

----------

Molten Ventures PLC - London-based venture capital firm - Completes GBP55.0 million placing and subscription of 20.4 million new shares priced at 270p each, representing around 13% of all shares. The retail offer remains open and is expected to close on Tuesday at 1500 GMT.

----------

Quadrise PLC - London-based residual oil technology company - Says all resolutions pass at annual general meeting, but notes resolution 3 only passed with 68% of shareholders voting in favour. Resolution 3 relates to re-appointing Non-Executive Director Dilip Shah, who is to retire by rotation. The company says on this: "The board is committed to continuing our engagement with shareholders to understand the views of those who voted against resolution 3 and will consult with them over the next few months to listen carefully to feedback and determine any next steps."

----------

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
11 May 2022 09:30

Syncona investee Freeline narrows quarterly loss as costs fall

(Alliance News) - Healthcare company investor Syncona Ltd on Wednesday noted that its portfolio company Freeline Therapeutics PLC trimmed its loss for the first quarter of 2022.

Read more
10 May 2022 14:26

IN BRIEF: Syncona investee Achilles widens quarterly loss on costs

Syncona Ltd - investor in healthcare companies - Notes investee company Achilles Therapeutics PLC posts widened loss amid rising research & development costs. Pretax loss in the quarter ended March 31 widens to USD17.3 million from USD13.8 million a year ago. Research & development costs surge to USD13.0 million from USD8.9 million, mainly due to increased activity in ongoing clinical trials. Cash and equivalents on March 31 fall to USD236.9 million from USD266.3 million as of December 31. "The company anticipates that its cash and cash equivalents are sufficient to fund its planned operations into the second half of 2024," Achilles says.

Read more
5 May 2022 12:59

IN BRIEF: Syncona's investee Autolus widens quarterly loss as costs up

Syncona Ltd - London-based healthcare & investment company - Reports quarterly loss for its portfolio company Autolus Therapeutics PLC as research costs rise. Net loss widens to USD42.7 million from USD39.0 million a year ago. Research & development expenses rise to USD34.0 million from USD30.7 million, Syncona explains.

Read more
28 Apr 2022 12:52

IN BRIEF: Syncona invests GBP15 million more in OMass Therapeutics

Syncona Ltd - London-based investment company - Invests more into OMass Therapeutics, an Oxford University biotechnology spin-out. After the new GBP15 million investment, Syncona now holds a 31% stake worth GBP44 million in the developer of small molecule drugs. The GBP15 million is part of an oversubscribed GBP75.5 million second round of funding for OMass, which now has raised GBP119 million in total.

Read more
28 Apr 2022 08:59

Syncona takes part in oversubscribed funding round for OMass

(Sharecast News) - Syncona committed further funding for rare-disease specialist OMass Therapeutics alongside a syndicate of investors which included a unit of French drug giant Sanofi.

Read more
11 Apr 2022 09:25

Syncona's investee Anaveon receives good trial data

(Alliance News) - Syncona Ltd on Monday noted that its portfolio company Anaveon AG received "encouraging" first clinical data from its ongoing phase I/II study for ANV419.

Read more
11 Apr 2022 07:49

Syncona's Anaveon to present first clinical data from ANV419 study

(Sharecast News) - Healthcare company Syncona said on Monday that its portfolio company, Anaveon AG, a clinical-stage immuno-oncology business, had announced that the first clinical data from the ongoing Phase I/II study of its lead programme, ANV419, would be presented in a poster at the American Association for Cancer Research's annual meeting in New Orleans.

Read more
1 Apr 2022 07:32

Syncona notes portfolio company Freeline annual loss widens in 2021

(Alliance News) - Syncona Ltd said on Friday that portfolio company Freeline Therapeutics Holdings PLC suffered a widened loss last year.

Read more
11 Mar 2022 08:44

Syncona to invest further USD20 million in Freeline Therapeutics

(Alliance News) - Syncona Ltd said on Friday that it agreed to invest USD20.0 million in Freeline Therapeutics Holdings PLC, as part of the investee's USD26.1 million American depositary shares offering.

Read more
18 Feb 2022 10:03

Syncona completes USD1.5 billion sale of Gyroscope to Novartis

(Alliance News) - Syncona Ltd on Friday said it has completed the sale of Gyroscope Therapeutics Holding PLC to Novartis AG.

Read more
10 Feb 2022 07:47

Syncona's Q3 a 'period of significant activity'

(Sharecast News) - Life sciences firm Syncona said on Thursday that the third quarter had been a "period of significant activity", with $674.0m raised by its portfolio and its third successful exit to date.

Read more
8 Feb 2022 20:38

IN BRIEF: Syncona's Freeline says FLT190 drug "well tolerated"

IN BRIEF: Syncona's Freeline says FLT190 drug "well tolerated"

Read more
22 Dec 2021 17:03

LONDON MARKET CLOSE: Omicron hope lifts FTSE despite UK virus surge

LONDON MARKET CLOSE: Omicron hope lifts FTSE despite UK virus surge

Read more
22 Dec 2021 12:21

LONDON MARKET MIDDAY: Stocks edge higher ahead of US growth figures

LONDON MARKET MIDDAY: Stocks edge higher ahead of US growth figures

Read more
22 Dec 2021 10:51

TOP NEWS SUMMARY: Novartis agrees to buy UK's Gyroscope Therapeutics

TOP NEWS SUMMARY: Novartis agrees to buy UK's Gyroscope Therapeutics

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.